Chapter 8 — Human Health And Disease

Fig 1 — Educational Diagram: Health and Disease

Definition of health: According to WHO (1948), health is "a state of complete physical, mental and social well‑being and not merely the absence of disease or infirmity." In practice health also includes metabolic and environmental well‑being and the ability to perform daily activities.

Definition of disease: A disease is any condition that impairs normal structure or function of an organism, producing signs and/or symptoms.

Types of disease:

• Infectious (communicable): Caused by pathogens (viruses, bacteria, fungi, protozoa, helminths). These can spread between hosts: e.g., tuberculosis (airborne), cholera (waterborne), malaria (vector‑borne).
• Non‑infectious (non‑communicable): Not spread by pathogens: e.g., diabetes, hypertension, cancer, genetic disorders, nutritional deficiencies.

Mode of transmission (infectious diseases): Direct contact (touch, droplet), airborne, faeco‑oral (contaminated food/water), vector‑borne (mosquito), fomite (inanimate objects).

Stages of infectious disease: Incubation (no symptoms), prodromal (early mild symptoms), illness (peak symptoms), decline (symptoms decrease), convalescence (recovery).

Host–pathogen interaction and defence:

• Innate immunity (non‑specific): Physical barriers (skin, mucous), chemical barriers (stomach acid), cellular responders (phagocytes, NK cells), inflammation, complement system. Rapid but not specific and has no memory.
• Adaptive immunity (specific): Humoral (B cells → antibodies) and cell‑mediated (T helper and cytotoxic T cells). Slower to develop but specific and has immunological memory.
• Types of acquired immunity: Natural active (infection), natural passive (maternal antibodies via placenta/breast milk), artificial active (vaccination), artificial passive (injection of antibodies/antitoxins).

Vaccination and herd immunity: Vaccines stimulate active immunity without causing disease (types: live attenuated, inactivated/killed, subunit/toxoid, conjugate, nucleic acid vaccines). Herd immunity occurs when sufficient proportion of population is immune, reducing spread and protecting unvaccinated individuals.

Prevention and control:

• Primary prevention: Health education, sanitation, vector control, vaccination, safe food/water.
• Secondary prevention: Early detection and screening, prompt treatment, quarantine/isolation when needed.
• Tertiary prevention: Rehabilitation, long‑term care, limiting complications.

Epidemiology — basic terms: incidence, prevalence, epidemic, endemic, pandemic, sporadic, case fatality rate. These quantify disease frequency and help plan control strategies.

Public health measures: Surveillance, vaccination programmes, vector control, sanitation, antibiotic stewardship (to delay resistance), health policies and education.

Class‑12 perspective — link to curriculum: Understand classification of diseases, immune responses (cells and molecules involved), vaccines and their role, modes of transmission, and simple epidemiological calculations (incidence, prevalence, R0 and herd immunity concept).

Fig 2 — Educational Diagram: Causes of Disease

Overview: Diseases arise when normal body function is disturbed. Causes can be broadly classified as infectious (caused by living agents) and non-infectious (caused by genetic, nutritional, environmental, lifestyle, or other factors). Most disease outcomes depend on interactions among the agent (if any), host susceptibility, and the environment.

Main categories and mechanisms:

• Infectious agents (pathogens): Bacteria, viruses, fungi, protozoa and helminths cause disease by invading tissues, multiplying, producing toxins, or triggering damaging immune responses. Modes of transmission include direct contact, droplet, airborne, vehicle (contaminated water/food), vector-borne and vertical (mother-to-child).
• Genetic causes: Inherited mutations or chromosomal abnormalities (single-gene defects, polygenic predispositions, chromosomal disorders) lead to disease by altering protein structure/function or developmental processes.
• Nutritional causes: Deficiencies (e.g., vitamin C, vitamin D, iron) or excesses (e.g., obesity from caloric excess) impair body processes and increase disease risk.
• Environmental and occupational causes: Physical (radiation), chemical (pollutants, heavy metals), and workplace exposures (silica, asbestos) cause toxic, inflammatory or carcinogenic effects.
• Lifestyle and behavioural causes: Smoking, alcohol, poor diet, lack of exercise, and risky sexual behaviour increase risk of chronic diseases, infections and cancers.
• Immune-related causes: Immunodeficiency (congenital or acquired, e.g., HIV/AIDS) increases susceptibility to infections; autoimmune reactions cause tissue damage (e.g., type 1 diabetes, rheumatoid arthritis).
• Iatrogenic causes: Adverse effects of medical treatments (drug side effects, surgical complications) and hospital-acquired infections (nosocomial) can cause disease.
• Psychosomatic and social determinants: Chronic stress, poverty, and poor sanitation contribute to disease risk by altering immunity, access to care, and exposure to hazards.

Chain of infection (conceptual model): agent → reservoir → portal of exit → mode of transmission → portal of entry → susceptible host. Breaking any link helps prevent spread.

Prevention principles: remove or treat the agent (antibiotics, antivirals, antifungals, deworming), reduce exposure (hygiene, sanitation, vector control, vaccines), strengthen host resistance (nutrition, immunization), and modify environment/behaviour (legislation, workplace safety, health education).

Fig 3 — Educational Diagram: Microorganisms in Health and Disease

Overview

Microorganisms (bacteria, viruses, fungi, protozoa and some algae) are microscopic life-forms that interact with humans in two main ways: beneficially (as normal flora, probiotics, decomposers and in biotechnology) and harmfully (as pathogens causing infectious diseases). Understanding their roles, modes of transmission and control measures is central to human health.

Microorganisms that promote health

• Normal flora (commensals): Microbes that colonize skin, gut, mouth and other sites without causing disease under normal conditions. They compete with pathogens and help in digestion and vitamin synthesis (e.g., gut bacteria producing vitamin K and some B vitamins).
• Probiotics and fermentation microbes: Lactobacillus and Bifidobacterium strains restore gut balance; Saccharomyces cerevisiae and starter cultures are used in food fermentation (yogurt, cheese, bread).
• Immune system development: Early microbial exposure helps train the immune response and maintain mucosal immunity.

Microorganisms that cause disease (pathogens)

Pathogens produce disease when they invade tissues, multiply and/or produce toxins. Disease severity depends on pathogen virulence, dose, route of entry and host immunity.

Modes of transmission

• Direct contact (touch, sexual contact) — e.g., herpes, syphilis.
• Indirect contact (fomites) — e.g., common cold spread via doorknobs.
• Droplet and airborne — e.g., influenza, tuberculosis.
• Fecal–oral — e.g., cholera, hepatitis A.
• Vector-borne — e.g., malaria (mosquito), dengue.
• Vertical (mother to child) — e.g., HIV, rubella congenitally.

Host–pathogen interactions

Pathogens adhere to host cells, evade or suppress host defenses, acquire nutrients and multiply. Host responses include innate immunity (barriers, phagocytes, inflammation) and adaptive immunity (antibodies, T cells). Clinical signs result from pathogen damage and immune reactions.

Koch’s postulates (historical criteria)

Robert Koch proposed criteria to link a microbe to a disease: the organism must be present in diseased cases, isolated and grown in pure culture, cause disease when introduced into a healthy host, and be re-isolated. Modern microbiology recognizes limitations (asymptomatic carriers, unculturable organisms) and supplements Koch’s ideas with molecular methods.

Diagnosis, treatment and prevention

• Diagnosis: Microscopy, culture, antigen/antibody tests, PCR and imaging.
• Treatment: Antibacterial (antibiotics), antiviral, antifungal and antiparasitic agents. Supportive care (fluids, oxygen) is often critical.
• Prevention: Vaccination, sanitation, safe water, hand hygiene, vector control, safe food handling and rational antibiotic use.
• Antibiotic resistance: Overuse/misuse selects resistant strains (e.g., MRSA, multidrug-resistant TB) — a major public-health challenge.

Public-health concepts

Incidence and prevalence measure disease frequency; R0 (basic reproduction number) estimates transmission potential of an infectious agent. Outbreak investigation and epidemiological surveillance guide control measures.

Summary

Microorganisms are essential for life and human health but can also cause disease. Prevention (hygiene, vaccination), correct diagnosis and responsible treatment are key to reduce disease burden and limit the spread of resistant strains.

Fig 4 — Educational Diagram: Modes of Transmission

Definition: Modes of transmission are the ways infectious agents (viruses, bacteria, parasites, fungi) move from a source (infected person, animal or reservoir) to a new host. Understanding modes helps in prevention and control of disease spread.

Major categories:

• Direct transmission – Immediate transfer of pathogen from an infected host to a susceptible host without an intermediate object or organism.
  • Direct contact: touch, sexual contact, blood contact (e.g., skin infections, HIV by unprotected sex or needle sharing).
  • Droplet: large respiratory droplets produced by coughs/sneezes that travel short distances (≈1–2 m) and deposit on mucous membranes (e.g., influenza, COVID-19 primarily via droplets).
  • Vertical (mother-to-child): across placenta, during childbirth or breastfeeding (e.g., HIV, congenital syphilis).
• Indirect transmission – Transfer via an intermediate vehicle, vector, or environmental medium.
  • Airborne: small droplet nuclei or particles that remain suspended and travel long distances (e.g., tuberculosis, measles).
  • Vehicle-borne: contaminated inanimate objects or substances (fomites: bedding, doorknobs; foodborne: salmonella; waterborne: cholera).
  • Vector-borne: living organisms (insects, ticks) that carry and transmit pathogens (e.g., malaria by Anopheles mosquitoes, dengue by Aedes).
• Nosocomial (hospital-acquired) – Infections acquired in healthcare settings often via invasive procedures, contaminated instruments, or cross-transmission by staff (e.g., MRSA, Clostridioides difficile).
• Zoonotic transmission – Pathogens transmitted between animals and humans (direct contact, bites, vector-mediated; e.g., rabies, certain influenza strains, COVID-19 likely originated zoonotically).

Key determinants of transmission:

• Pathogen factors: infectious dose, stability in environment, route of entry.
• Host factors: immune status, behaviour (handwashing, mask use), susceptibility.
• Environmental factors: crowding, ventilation, sanitation, vector presence, seasonality.

Prevention & control principles:

• Interrupt direct transmission: isolation, barrier nursing, condoms, safe injection practices.
• Interrupt indirect transmission: hand hygiene, surface disinfection, safe water/food handling, vector control (nets, insecticides), air filtration and ventilation.
• Vaccination to reduce susceptible pool and lower effective transmission (Rt).

How this links to epidemiology: Modes of transmission determine the shape of outbreaks, appropriate public health interventions and which epidemiological measures (incidence, prevalence, R0) are most informative for control.

Fig 5 — Educational Diagram: Common Infectious Diseases — Examples

What are common infectious diseases? Infectious diseases are disorders caused by pathogenic microorganisms — bacteria, viruses, fungi or parasites — that can be spread, directly or indirectly, from one person to another or from animals or the environment to people. Classifying and understanding examples helps in prevention, diagnosis and control.

Major components to consider

• Causative agent: bacterium (e.g., Salmonella typhi), virus (e.g., Influenza virus), parasite (e.g., Plasmodium spp.), fungus (e.g., Trichophyton spp.).
• Modes of transmission: feco-oral (contaminated water/food), airborne/droplet, direct contact, vector-borne (mosquitoes, ticks), sexual, blood-borne.
• Incubation period: time between exposure and symptoms — important for quarantine and diagnosis.
• Clinical features: range from mild (common cold) to severe (tuberculosis, HIV/AIDS); symptoms guide initial treatment.
• Prevention and control: vaccination, sanitation, safe water, vector control, personal hygiene, safe sex, use of antibiotics/antivirals when indicated and stewardship to prevent resistance.

How the body defends — innate immunity (skin, mucous, phagocytes) and adaptive immunity (antibodies, cell-mediated response). Vaccination trains adaptive immunity to recognise pathogens without causing disease.

Treatment principles — use of specific antimicrobials: antibiotics for bacteria, antivirals for some viral infections, antifungals for fungal infections, antiprotozoal drugs for parasites. Supportive care (e.g., oral rehydration for diarrhoea) is often critical.

Public health role — surveillance, outbreak investigation, vaccination programmes, health education, environmental sanitation and vector control reduce incidence and spread.

Short summary: Knowing typical examples, their agents, transmission modes and control measures helps students apply these concepts to clinical or public-health scenarios and understand CBSE-level questions on human health and disease.

Fig 6 — Educational Diagram: Non-infectious Diseases and Lifestyle Disorders

Definition: Non-infectious diseases (also called non-communicable diseases, NCDs) are disorders that are not caused by infectious agents and cannot be transmitted between people. Lifestyle disorders are a subcategory of NCDs whose principal causes are behavioral or environmental risk factors (diet, physical inactivity, tobacco, alcohol, stress).

Main categories:

• Genetic disorders: caused by mutations or chromosomal abnormalities (e.g., sickle cell anemia, hemophilia, Down syndrome).
• Deficiency diseases: due to lack of essential nutrients (e.g., scurvy—vitamin C deficiency; rickets—vitamin D deficiency; iron-deficiency anemia).
• Metabolic/endocrine disorders: e.g., diabetes mellitus (particularly type 2), obesity, thyroid disorders.
• Cardiovascular diseases (CVD): e.g., hypertension, coronary artery disease, myocardial infarction, stroke—often related to atherosclerosis.
• Chronic respiratory diseases: e.g., COPD, chronic bronchitis, emphysema—commonly linked to smoking and pollution.
• Cancer (neoplasia): abnormal cell growth due to genetic and environmental risk factors (smoking, radiation, diet).
• Autoimmune and allergic diseases: e.g., rheumatoid arthritis, type 1 diabetes (autoimmune), asthma (allergic component).

Key mechanisms and examples:

• Atherosclerosis: deposition of cholesterol and lipids in arterial walls → plaque formation → narrowing of lumen → reduced blood flow. Progressive narrowing greatly increases vascular resistance (even small decreases in vessel radius drastically reduce flow).
• Insulin resistance and type 2 diabetes: excess adiposity, sedentary lifestyle and poor diet lead to decreased insulin sensitivity. Chronic hyperglycemia causes vascular damage, neuropathy and increased infection risk.
• Obesity: excess energy intake vs expenditure causes adipose expansion, metabolic changes (inflammation, dyslipidemia) that raise risk of diabetes, hypertension and CVD.
• Carcinogenesis: accumulation of DNA damage and failures in repair/apoptosis give rise to uncontrolled proliferation; lifestyle factors (tobacco, alcohol, diet, UV) increase mutation load.

Clinical features & diagnosis: Symptoms depend on disease (chest pain, breathlessness, polyuria, polydipsia, unexplained weight loss/gain). Diagnosis uses clinical exam, biochemical tests (blood glucose, lipid profile), imaging (ECG, angiography, CT) and histopathology for cancers.

Prevention and management:

• Primary prevention: healthy diet (low saturated fat, adequate fruits/vegetables), regular physical activity, avoiding tobacco and excessive alcohol, maintaining healthy weight.
• Secondary prevention: screening for hypertension, diabetes, hyperlipidemia; early treatment to prevent complications.
• Tertiary care: medications (antihypertensives, statins, insulin/oral hypoglycemics), surgical interventions (angioplasty, bypass, tumor resection), rehabilitation and lifestyle counseling.

Public health perspective: NCDs are the leading cause of mortality worldwide; they are chronic, costly, and largely preventable by population-level policy (tobacco control, healthy food access, active transport).

Connections to CBSE Class 12 syllabus: Understand differences between infectious and non-infectious disease, major examples and mechanisms (e.g., atherosclerosis, insulin resistance), role of lifestyle factors, prevention strategies and the importance of early diagnosis and health education.

Fig 7 — Educational Diagram: Defense Mechanisms — Overview

Overview: Defence mechanisms are the body's strategies to prevent infection and eliminate pathogens. They operate at two broad levels: innate (nonspecific) immunity — immediate, general protection present from birth — and adaptive (specific) immunity — slower to develop but highly specific and with memory.

Innate immunity (first and second lines of defence):

• Physical and chemical barriers (first line): skin, mucous membranes, tears, saliva, acidic stomach, normal microbiota that compete with pathogens.
• Cellular components (second line): phagocytes (neutrophils, macrophages) that ingest microbes; natural killer (NK) cells that kill infected or cancerous cells.
• Inflammation and fever: local response — vasodilation, increased vascular permeability, leukocyte recruitment — that helps isolate and remove pathogens. Fever raises body temperature to inhibit microbe growth and stimulate immune activity.
• Soluble factors: complement proteins (opsonization, membrane attack complex), interferons (antiviral signalling), acute phase proteins.

Adaptive immunity (third line of defence):

• Humoral immunity: mediated by B lymphocytes that differentiate into plasma cells producing antibodies (immunoglobulins). Antibodies neutralize pathogens, opsonize for phagocytosis, and activate complement.
• Cell-mediated immunity: mediated by T lymphocytes — helper T cells (CD4+) activate B cells and macrophages; cytotoxic T cells (CD8+) kill infected cells.
• Clonal selection and memory: antigen stimulates specific B or T cell clones which proliferate (clonal expansion). Some become long‑lived memory cells producing a faster, stronger response on re-exposure (secondary response).
• Active vs passive immunity: active — host produces its own immune response (natural infection or vaccination); passive — transfer of ready-made antibodies (maternal IgG across placenta, IgA in breast milk, or therapeutic antiserum) giving immediate, short-term protection.

Failures and dysregulation: Allergies/hypersensitivities are overreactions (e.g., IgE-mediated hay fever); autoimmune diseases result from loss of self-tolerance (e.g., rheumatoid arthritis, type I diabetes); immunodeficiencies (congenital or acquired like HIV) reduce ability to fight infections.

Principles of vaccination: Vaccines present antigen in safe form to induce primary adaptive response and memory, so that on real exposure a rapid secondary response prevents disease. Herd immunity depends on sufficient population immunity to reduce transmission.

Key concepts to remember: innate = fast, nonspecific, no memory; adaptive = slow at first, specific, memory. Effective defence usually requires cooperation of both arms.

Fig 8 — Educational Diagram: Innate Immunity

Definition: Innate immunity is the body’s first line of defence against infectious agents. It is present from birth, acts immediately or within hours of an antigen’s appearance, is non‑specific, and does not generate immunological memory.

Key features:

• Rapid (minutes–hours), non‑specific recognition of threats.
• No memory — same response on repeated exposure.
• Uses physical, chemical, cellular and humoral mechanisms.

Main components:

• Physical and mechanical barriers: Intact skin, mucous membranes, mucus, cilia (respiratory tract), flushing actions (tears, urine).
• Chemical barriers: Lysozyme (tears, saliva), low pH of stomach, antimicrobial peptides (defensins), surfactant proteins in lungs.
• Microbial flora: Commensal bacteria on skin and mucosa that compete with pathogens.
• Cellular defences:
  • Neutrophils — first recruited, phagocytose and kill bacteria.
  • Macrophages — phagocytosis, antigen presentation, cytokine production.
  • Dendritic cells — bridge innate and adaptive systems by presenting antigen.
  • Natural killer (NK) cells — kill virus‑infected and tumor cells via perforin/granzymes; recognise ‘missing self’ (low MHC I).
  • Eosinophils and mast cells — important against parasites and in allergy/inflammation.
• Humoral factors:
  • Complement system (classical, lectin, alternative pathways) — opsonisation, inflammation, membrane attack complex (lysis of some microbes).
  • Interferons (especially type I IFNs) — antiviral state in neighbouring cells.
  • Acute phase proteins (e.g., C‑reactive protein) — opsonisation and modulation of inflammation.
  • Cytokines (e.g., IL‑1, TNF‑α, IL‑6) — mediate inflammation, fever, and leukocyte recruitment.

Recognition mechanism: Innate cells detect conserved molecular patterns on microbes called PAMPs (pathogen‑associated molecular patterns) via PRRs (pattern recognition receptors) such as Toll‑like receptors (TLRs). This triggers phagocytosis, cytokine release and activation of downstream responses.

Inflammation (basic steps): Tissue injury or infection → detection by resident macrophages/dendritic cells → release of cytokines/chemokines → vasodilation and increased vascular permeability → recruitment of neutrophils and monocytes → phagocytosis and killing of microbes → resolution and repair (or chronic inflammation if unresolved).

Outcome: If innate mechanisms reduce pathogen numbers sufficiently, infection is controlled and adaptive immunity may not be strongly engaged. If not, innate responses activate and shape adaptive immunity (T and B cell responses).

Clinical relevance / examples of defects: Defects in innate components cause susceptibility to infections — e.g., chronic granulomatous disease (defect in NADPH oxidase → impaired killing by phagocytes), complement deficiencies (C3 deficiency → recurrent pyogenic infections).

Fig 9 — Educational Diagram: Inflammation and Fever

Overview
Inflammation is the local tissue response to injury or infection whose purpose is to eliminate the initial cause of cell injury, clear out damaged cells and tissues, and establish repair. Fever is a systemic response in which the hypothalamic set point for body temperature is raised, usually in response to infection or inflammation.

Acute inflammation: cardinal signs

• Rubor (redness) – due to vasodilation and increased blood flow.
• Calor (heat) – increased blood flow and metabolism at the site.
• Tumor (swelling) – due to increased vascular permeability and accumulation of fluid (exudate).
• Dolor (pain) – sensitization of nerve endings by mediators (eg, bradykinin, prostaglandins).
• Loss of function – from pain and tissue damage.

Key steps and cellular events

1. Recognition of injurious agent – by resident cells (macrophages, dendritic cells) via pattern recognition receptors (eg, TLRs) recognizing PAMPs and DAMPs.
2. Vasodilation – mediated by histamine, nitric oxide and prostaglandins. Causes redness and heat.
3. Increased vascular permeability – plasma proteins and fluid leak into tissues producing exudate and swelling.
4. Leukocyte recruitment and migration – steps include margination, rolling (selectins), adhesion (integrins), diapedesis and chemotaxis (eg, C5a, IL-8).
5. Phagocytosis and killing – neutrophils and macrophages ingest microbes/debris; killing via reactive oxygen species, nitric oxide, lysosomal enzymes.
6. Resolution or outcome – complete resolution (restoration), healing by fibrosis (scar), abscess formation, or progression to chronic inflammation if injurious agent persists.

Mediators of inflammation
Major mediators include histamine, bradykinin, prostaglandins, leukotrienes, nitric oxide, complement fragments (C3a, C5a), cytokines (eg, IL-1, TNF-α) and chemokines. These are produced by resident cells, recruited leukocytes and plasma protein systems (complement, clotting, kinin).

Chronic inflammation
Occurs when the acute response fails to eliminate the cause. Characterized by predominance of macrophages, lymphocytes, plasma cells, tissue destruction, and attempts at repair with fibrosis (eg, tuberculosis, rheumatoid arthritis).

Fever (pyrexia)

Definition and cause
Fever is an elevation of body temperature due to an increase in the hypothalamic thermoregulatory set point. Common triggers are infection (bacteria, viruses, parasites), inflammatory diseases, malignancy and some drugs.

Pyrogens

• Exogenous pyrogens – microbial products such as lipopolysaccharide (LPS).
• Endogenous pyrogens – cytokines produced by host cells in response to infection or injury (eg, IL-1, IL-6, TNF-α). These act via production of prostaglandin E2 (PGE2) in the hypothalamus to raise the temperature set point.

Mechanism
Endogenous pyrogens increase PGE2 in the preoptic area of hypothalamus → hypothalamic set point rises → physiological responses to reach new set point: peripheral vasoconstriction, shivering, increased metabolism, and behavioral changes (seeking warmth). When infection or inflammation resolves, set point returns to normal → vasodilation and sweating reduce temperature.

Patterns of fever

• Continuous (remains above normal with little variation) – eg, typhoid.
• Remittent (fluctuates but never returns to normal) – many bacterial infections.
• Intermittent (normal at intervals) – eg, malaria.
• Relapsing (periods of fever separated by days or weeks) – eg, certain infections like relapsing fever.

Physiological effects, benefits and dangers
Moderate fever enhances immune function (increases leukocyte activity and impairs growth of some pathogens). High fever can cause dehydration, increased metabolic demand, delirium, seizures (especially in young children) and organ dysfunction if prolonged.

Treatment and management
Antipyretics: paracetamol (acetaminophen) and NSAIDs (eg, ibuprofen) lower PGE2 and reduce set point. Supportive measures: adequate hydration, antipyretics, tepid sponging (when appropriate), cooling for very high fevers, and treating the underlying cause (eg, antibiotics for bacterial infection).

Important clinical correlations

• Appendicitis: localized acute inflammation of the appendix with pain, tenderness and systemic signs.
• Rheumatoid arthritis: example of chronic immune-mediated inflammation with joint destruction.
• Sepsis: systemic inflammatory response to infection that can lead to multi-organ dysfunction and shock.

Summary: Inflammation is a complex host response aimed at removing harmful stimuli and starting repair. Fever is a systemic, regulated rise in body temperature driven by pyrogenic mediators. Both are components of the body s defense but may cause harm if excessive or uncontrolled.

Fig 10 — Educational Diagram: Adaptive Immunity — Overview

Adaptive immunity (also called acquired or specific immunity) is the arm of the immune system that recognizes specific foreign molecules (antigens), mounts a targeted response, and retains memory for faster, stronger responses on re-exposure. It complements innate immunity and develops after contact with pathogens or vaccines.

Key characteristics

• Specificity: Recognizes specific antigenic determinants (epitopes).
• Memory: Produces a faster and larger response on subsequent exposures (secondary response).
• Self–nonself discrimination: Tolerance to self antigens; reacts to nonself.
• Diversity: Can recognize vast numbers of different antigens.

Main components

• Humoral immunity (B lymphocytes): B cells recognize antigens (often with T help), differentiate into plasma cells that secrete antibodies (immunoglobulins IgM, IgG, IgA, IgE, IgD) and generate memory B cells.
• Cell-mediated immunity (T lymphocytes): T cells act against infected cells, cancer cells and help other immune cells. Major types: helper T cells (CD4+, activate B cells and macrophages), cytotoxic T cells (CD8+, kill infected cells), regulatory T cells (suppress responses).
• Antigen-presenting cells (APCs): Dendritic cells, macrophages and B cells process antigens and present peptide fragments on major histocompatibility complex (MHC) molecules to T cells. MHC I presents to CD8+; MHC II presents to CD4+.

How adaptive immunity works (overview of sequence)

• Antigen entry & capture by APCs.
• Antigen processing and presentation on MHC molecules.
• Activation of naive T cells (helper and cytotoxic) and B cells (with T helper cell assistance for T-dependent antigens).
• Clonal expansion and differentiation: effector cells (plasma cells and cytotoxic T cells) + memory cells.
• Elimination of pathogen and formation of long-lived memory cells.

Clonal selection (concise)

Each lymphocyte bears antigen receptors of a single specificity. Encounter with its specific antigen (plus co-stimulation) causes that clone to proliferate (clonal expansion) and form effector and memory cells. This explains specificity and memory.

Primary vs secondary response

Primary response: first exposure produces a lag phase, initial IgM production followed by IgG; lower magnitude. Secondary response: memory cells produce a rapid, high-magnitude response dominated by high-affinity IgG (or other isotypes), often preventing disease.

Clinical relevance

• Vaccination: deliberate exposure to antigen to create memory without disease.
• Autoimmunity: failure of self–nonself discrimination leads to attacks on self tissues.
• Transplant rejection: cell-mediated recognition of nonself MHC causes graft rejection.
• Immunodeficiency: defects in adaptive components (e.g., B- or T-cell deficiencies) increase susceptibility to infections.

Summary line: Adaptive immunity is a specific, memory-forming immune system involving B- and T-lymphocytes, antigen presentation via MHC, clonal selection, and distinct primary and secondary antibody responses that underpin vaccination and long-term protection.

Fig 11 — Educational Diagram: Cells and Organs of the Immune System

Overview

The immune system protects the body from pathogens and damaged cells by coordinated action of specialised cells and organs. Cells of the immune system arise from hematopoietic stem cells in bone marrow and are broadly classified into innate (non-specific, rapid) and adaptive (specific, memory-forming) components. Organs are divided into primary (where immune cells develop) and secondary (where immune responses are initiated).

Primary lymphoid organs

• Bone marrow: Site of hematopoiesis. B lymphocytes mature here in humans; myeloid lineages (neutrophils, monocytes, eosinophils, basophils, mast cells) are also produced.
• Thymus: T lymphocyte maturation and selection (positive and negative selection) occur here. Functional size reduces (involution) after puberty.

Secondary lymphoid organs

• Lymph nodes: Filter lymph, concentrate antigens; site of interactions between antigen-presenting cells, T cells and B cells leading to activation and clonal expansion.
• Spleen: Filters blood-borne antigens; contains white pulp (immune reactions) and red pulp (removal of old RBCs).
• Mucosa-associated lymphoid tissue (MALT): Tonsils, Peyer’s patches, appendix — protect mucosal entry points.

Cells of innate immunity

• Neutrophils: Phagocytic first responders; kill bacteria by phagocytosis and release of reactive oxygen species. Most abundant WBC.
• Macrophages: Phagocytose pathogens and dead cells; present antigen to T cells (as antigen-presenting cells, APCs); secrete cytokines to recruit cells.
• Dendritic cells: Potent APCs that capture antigen in tissues and migrate to lymph nodes to activate naive T cells.
• Natural Killer (NK) cells: Kill virus-infected and tumour cells without prior sensitisation (recognise missing MHC I).
• Eosinophils, basophils, mast cells: Involved in parasitic infections and allergic responses (release histamine, major basic protein, etc.).

Cells of adaptive immunity

• B lymphocytes (B cells): Recognise antigen (often with T-cell help), differentiate into plasma cells that secrete antibodies (humoral immunity). Some become memory B cells.
• T lymphocytes (T cells):
  • CD4+ Helper T cells (TH): help B cells and macrophages by cytokines; subtypes (TH1, TH2, TH17) direct type of response.
  • CD8+ Cytotoxic T cells (TC): kill infected or altered self-cells presenting antigen on MHC I (cell-mediated immunity).
  • Regulatory T cells (Treg): suppress immune responses to maintain self-tolerance and prevent autoimmunity.
• Plasma cells: Antibody factories derived from activated B cells.
• Memory cells: Long-lived B and T cells that provide rapid, stronger secondary responses on re-exposure.

Key interactions and processes

• Antigen presentation: APCs (dendritic cells, macrophages, B cells) process antigen and present peptides on MHC molecules—MHC I for CD8+ T cells; MHC II for CD4+ T cells.
• Clonal selection and expansion: A specific lymphocyte recognising its antigen is activated, proliferates (clonal expansion) and differentiates into effector and memory cells.
• Humoral vs cell-mediated immunity: Humoral—antibodies neutralise extracellular pathogens and toxins. Cell-mediated—cytotoxic T cells and macrophages clear intracellular pathogens and infected cells.

Clinical correlations

• Vaccination: Uses an antigen to generate memory B and T cells so that a faster and higher secondary response protects upon real infection.
• Allergy: Excessive IgE-mediated mast cell degranulation (histamine) causes symptoms like asthma, hay fever.
• Autoimmunity: Failure of self-tolerance (e.g., rheumatoid arthritis, type 1 diabetes) where immune cells attack self-tissues.
• Immunodeficiency: Primary (genetic) or secondary (e.g., HIV infects CD4+ T cells) leads to susceptibility to infections.

Understanding the cells and organs together explains how the body recognises, responds to, remembers and resolves infections—core concepts tested in Class 12 Biology.

Fig 12 — Educational Diagram: Antigens and Epitopes

Antigen (Ag): Any molecule or molecular fragment that can specifically bind to components of the immune system (antibodies or T‑cell receptors) and may provoke an immune response. Typical antigens are proteins or large polysaccharides; small molecules (haptens) are antigenic only when covalently attached to a carrier.

Epitope (Antigenic Determinant): A specific portion of an antigen that is recognized and bound by an antibody or a T‑cell receptor. One antigen molecule can contain several different epitopes.

Key distinctions

• B‑cell (antibody) epitopes: usually accessible regions on the native 3D surface of the antigen. They can be linear (continuous amino‑acid stretches) or conformational/discontinuous (brought together by protein folding).
• T‑cell epitopes: short linear peptides produced by antigen processing and presented on MHC molecules to T‑cell receptors.

Properties that determine antigenicity/immunogenicity

• Foreignness: more foreign → more antigenic.
• Size: larger molecules (>10 kDa, especially proteins) are better immunogens.
• Chemical complexity and heterogeneity: more complex → better.
• Dose, route and adjuvants: affect the magnitude and type of response.

Antigen–antibody interaction: Binding is non‑covalent (hydrogen bonds, ionic interactions, hydrophobic effects, van der Waals). Multiple binding sites on antibodies (bivalent IgG, pentameric IgM) lead to avidity (overall strength) which depends on individual binding affinity and valency.

Clinical and biological significance

• Vaccine design: selection of protective epitopes to elicit neutralizing antibodies or T‑cell responses.
• Allergy and hypersensitivity: small antigenic determinants (allergens) trigger IgE‑mediated responses.
• Blood transfusion and transplantation: recognition of blood group antigens and HLA epitopes causes rejection or hemolytic reactions.
• Autoimmunity: immune recognition of self‑epitopes leads to disease.
• Diagnostics: assays (ELISA, Western blot) detect antigen–antibody binding using known epitopes.

Additional notes: Haptens (e.g., some drugs like penicillin) become antigenic after binding host protein. Cross‑reactivity occurs when unrelated antigens share similar epitopes. Affinity maturation in B cells increases antibody affinity for an epitope over time after repeated antigen exposure.

Fig 13 — Educational Diagram: Antibodies — Structure and Function

Overview
Antibodies (immunoglobulins, Igs) are Y-shaped glycoproteins produced by B cells (plasma cells) that specifically bind antigens to neutralize pathogens and mark them for elimination. They are central to humoral immunity and are produced during primary and secondary immune responses.

Basic structure

• Each antibody is composed of four polypeptide chains: two identical heavy (H) chains and two identical light (L) chains linked by disulfide bonds. Typical molecular mass: IgG ≈ 150 kDa (H ≈ 50 kDa, L ≈ 25 kDa).
• Each chain has a variable (V) region at the N-terminus and one or more constant (C) domains at the C-terminus. The variable regions of one heavy + one light chain form an antigen-binding site.
• Complementarity determining regions (CDRs, three in each V domain) form the actual antigen-contact loops — 6 CDRs make one paratope.
• Functionally the antibody splits into: Fab (fragment antigen binding) — contains V and first C domain of H and L chains and binds antigen; Fc (fragment crystallizable) — composed of C domains of heavy chains, mediates effector functions (complement activation, Fc receptor binding).
• Hinge region between CH1 and CH2 gives flexibility. Heavy chains have 3 or 4 constant domains depending on isotype (IgG, IgA, IgD: 3; IgM, IgE: 4).

Major isotypes and key functions

• IgG – monomer, most abundant in serum, crosses placenta (provides neonatal immunity), opsonization, neutralization, complement activation; half-life ≈ 21 days.
• IgM – secreted as a pentamer (with J chain), first antibody produced in primary response, very effective at agglutination and activating complement.
• IgA – in secretions (dimeric in mucosal secretions with secretory component), protects mucosal surfaces (saliva, tears, breast milk).
• IgE – monomer, binds Fc receptors on mast cells and basophils, mediates allergic responses and defense vs helminths.
• IgD – mainly B-cell receptor on naive B cells; role in B-cell activation.

How antibodies work (mechanisms)

• Neutralization: antibody blocks pathogen attachment or toxin activity (e.g., antitoxin antibodies).
• Agglutination/Precipitation: cross-linking of antigens into complexes that are cleared more easily.
• Opsonization: Fc region binds phagocyte Fc receptors enhancing phagocytosis.
• Complement activation: Fc region (mainly IgM and IgG) triggers classical complement pathway leading to lysis or opsonization.
• Antibody-dependent cell-mediated cytotoxicity (ADCC): NK cells recognize Fc-bound antibody and kill the target cell.

Generation of antibody diversity

• V(D)J recombination: random somatic recombination of Variable (V), Diversity (D, heavy chain only), and Joining (J) gene segments during B-cell development (mediated by RAG1/2 enzymes) forms diverse V regions.
• Junctional diversity: nucleotide addition/deletion at joining sites increases variability.
• Somatic hypermutation and affinity maturation: activation-induced cytidine deaminase (AID) introduces point mutations in variable regions of activated B cells in germinal centers; B cells with higher-affinity receptors are selected.
• Class (isotype) switching: AID-mediated recombination changes heavy-chain constant region (e.g., from μ to γ, α, ε) so the same antigen specificity can be expressed with different effector functions (IgM → IgG/IgA/IgE) under cytokine control.

Primary vs secondary immune response
In a primary response, IgM appears first then IgG; in a secondary (memory) response, IgG rises faster and to higher levels and affinity is greater due to memory B cells and affinity maturation.

Clinical and practical notes

• Passive immunity: transfer of antibodies (e.g., maternal IgG via placenta; antivenoms and immunoglobulin therapy) provides immediate short-term protection.
• Vaccination stimulates active immunity and memory B cells that produce high-affinity IgG on re-exposure.
• Monoclonal antibodies (mAbs) are engineered antibodies used as therapeutics (e.g., rituximab for CD20+ B-cell lymphoma, trastuzumab for HER2+ breast cancer) and diagnostics.
• Autoimmune diseases often involve pathogenic autoantibodies (e.g., rheumatoid factor, anti-thyroid antibodies).

Key facts summary

• Antigen-binding site = variable regions of heavy + light chains; 6 CDRs per site.
• Fab = antigen binding; Fc = mediates effector functions.
• IgM = primary response, pentameric; IgG = major serum Ab & memory response; IgA = mucosal; IgE = allergy; IgD = BCR.

Fig 14 — Educational Diagram: Classes of Immunoglobulins

Introduction
Immunoglobulins (Igs) or antibodies are glycoprotein molecules produced by plasma cells in response to antigens. In humans there are five major classes: IgG, IgM, IgA, IgE and IgD. Each class differs in structure, location, function and abundance. These differences determine how the immune system neutralises pathogens, activates complement, mediates allergy and provides passive immunity.

Overview of structure (common features)

• Basic unit: four polypeptide chains — 2 heavy (H) chains + 2 light (L) chains forming a Y-shaped molecule with two antigen-binding (Fab) arms and one Fc region.
• Variable (V) regions at tips bind antigen; constant (C) regions determine class and effector functions.
• Forms: monomers or polymers (dimer, pentamer) joined by J (joining) chain; secretory IgA has an extra secretory component for mucosal transport.

Class-wise details

IgG

• Structure: monomer (~150 kDa).
• Abundance: most abundant in serum (~70–75% of total Ig).
• Functions: opsonisation, neutralisation of toxins and viruses, complement activation (mainly subclasses IgG1 & IgG3), antibody-dependent cell-mediated cytotoxicity (ADCC).
• Special feature: crosses the placenta — provides passive immunity to the fetus; long half-life (~21 days).
• Role in immune response: principal antibody of secondary (memory) response; high affinity after class switching and affinity maturation.

IgM

• Structure: primary form is pentamer in serum (5 monomers + J chain) — very large (~900 kDa).
• Abundance: ~5–10% of serum Ig.
• Functions: very effective at agglutination and at activating the classical complement pathway (one IgM pentamer bound to antigen can efficiently activate complement).
• Special feature: first antibody produced in a primary immune response; appears early but is short-lived (half-life ~5 days).
• Valency: pentameric valency ≈10 antigen-binding sites (steric/functional valency often fewer).

IgA

• Structure: serum IgA is mostly a monomer; secretory IgA (sIgA) in mucous secretions is a dimer joined by J chain and secretory component.
• Abundance: ~10–15% of serum Ig but is the main antibody class in mucosal secretions (saliva, tears, gut, bronchial secretions, breast milk).
• Functions: neutralisation at mucosal surfaces, prevents attachment of pathogens to epithelial cells; protects neonates via breast milk (sIgA).
• Half-life: serum IgA ~6 days (approx.).

IgE

• Structure: monomer.
• Abundance: extremely low in serum (<0.01% of total Ig).
• Functions: binds to high-affinity Fc receptors on mast cells and basophils; cross-linking by allergen triggers degranulation and release of histamine — central to allergic (type I hypersensitivity) reactions and defence against helminths.
• Half-life: short (~2 days in serum; longer when bound to Fc receptors on cells).

IgD

• Structure: monomer; found on surface of naive B cells as B-cell receptor (BCR).
• Abundance: very low in serum.
• Functions: role mainly as membrane receptor involved in B cell activation and signalling; serum function not well defined.

Functional summary

• Primary immune response: IgM is produced first; later class switch leads to IgG, IgA or IgE depending on cytokine signals.
• Secondary (memory) response: rapid and larger production of high-affinity IgG (and other switched classes) due to memory B cells.
• Complement activation: classical pathway activated effectively by IgM and certain IgG subclasses.
• Passive immunity: maternal IgG transferred via placenta; sIgA transferred in breast milk protects infant gut.

Key clinical relevance: measurement of Ig classes helps diagnose immunodeficiencies (e.g., low IgA), allergic disease (elevated IgE), recent infection (high IgM) and past exposure or vaccine response (IgG). Therapeutic monoclonal antibodies are mostly IgG isotypes because of long half-life and effector functions.

Fig 15 — Educational Diagram: B-cell Responses and Antibody Production

B-cell responses — overview

B lymphocytes (B cells) are the main cells of humoral immunity. They recognise antigens through surface B-cell receptors (BCRs; membrane-bound immunoglobulins), become activated, proliferate (clonal expansion) and differentiate into antibody-secreting plasma cells and long-lived memory B cells. The antibodies (immunoglobulins, Ig) produced neutralise pathogens, opsonise them for phagocytosis, activate complement and mediate other effector functions.

Steps of B-cell activation and antibody production

• Antigen recognition: BCR binds specific antigen (native/soluble or on pathogen surface).
• Antigen internalisation and presentation: Antigen–BCR complex is internalised; peptides are presented on MHC class II molecules on the B cell surface.
• T-helper (Th) cell help – T-dependent activation: Helper T cells (usually Th2) with TCR specific for the same antigen/MHC II interact with the B cell and provide co-stimulatory signals (CD40L–CD40) and cytokines (IL-4, IL-5, IL-21). This leads to strong activation, germinal centre reactions and memory formation.
• T-independent activation: Some antigens (e.g., repetitive bacterial polysaccharides) can cross-link many BCRs and activate B cells without T-cell help; mostly IgM responses with limited memory.
• Clonal expansion: Activated B cells proliferate to produce many identical clones (clonal selection principle).
• Germinal centre reactions: In secondary lymphoid organs, B cells undergo somatic hypermutation (in variable-region genes) and affinity maturation, and class (isotype) switching under cytokine influence. High-affinity clones are selected.
• Differentiation: Some B cells become plasma cells (antibody factories), others become memory B cells for faster secondary responses.

Antibody structure and classes

Antibodies are Y-shaped molecules made of two identical heavy chains and two identical light chains. Each arm has a variable (V) region that binds antigen (Fab) and a constant (C) region (Fc) that mediates effector functions. Main human isotypes and typical functions:

• IgM: First antibody in primary response, pentameric (high avidity), good at complement activation.
• IgG: Most abundant in serum, opsonisation, complement activation, crosses placenta (provides neonatal immunity).
• IgA: Dimeric in secretions (saliva, mucus, breast milk); protects mucosal surfaces.
• IgE: Binds mast cells/basophils, mediates allergic responses and protection against parasites.
• IgD: Mostly membrane-bound on naïve B cells (role in activation).

Mechanisms of antibody-mediated protection

• Neutralisation: Antibodies block pathogen attachment/entry or toxin activity.
• Agglutination/precipitation: Cross-linking pathogens or soluble antigens to facilitate clearance.
• Opsonisation: Antibody Fc binds Fc receptors on phagocytes, enhancing phagocytosis.
• Complement activation: Classical pathway activation leading to lysis or opsonisation.
• Antibody-dependent cellular cytotoxicity (ADCC): NK cells recognise antibody-coated targets and kill them.

Primary vs secondary (memory) responses

Primary response: first exposure → lag phase (days), low-to-moderate IgM then IgG levels. Secondary response (upon re-exposure or booster): much shorter lag, faster and larger production of high-affinity IgG (and other switched isotypes) because memory B cells respond rapidly and germinal-centre-derived high-affinity clones are available.

Important molecular processes

• V(D)J recombination: Generates BCR/antibody diversity during B-cell development.
• Somatic hypermutation: Point mutations in V regions during germinal-centre reactions increase affinity.
• Class (isotype) switching: DNA recombination in heavy-chain constant region under cytokine control (e.g., IL-4 promotes switching to IgE; TGF-β can promote IgA).

Clinical and practical relevance

Vaccination mimics primary exposure to create memory B cells so that booster or real infection elicits a rapid, high-affinity secondary response. Monoclonal antibodies (lab-produced) are used as diagnostics and therapeutics. Defects in B-cell development or function (e.g., agammaglobulinemia, common variable immunodeficiency) lead to recurrent infections. Allergies are caused by inappropriate IgE responses.

Note for students: Understand the sequence of events (recognition → activation → clonal expansion → differentiation) and the differences between Ig classes and primary vs secondary responses. Diagrams of antibody structure and antibody–time curves are very helpful.

Fig 16 — Educational Diagram: T-cell Mediated Immunity

Overview

T-cell mediated immunity (cell-mediated immunity) is the arm of adaptive immunity in which T lymphocytes (T cells) recognise and eliminate infected cells, abnormal cells (tumour), and coordinate other immune cells. Unlike B cells that produce antibodies, T cells act mainly by direct cell-to-cell contact and by secreting cytokines.

Types of T cells and functions

• CD8+ Cytotoxic T lymphocytes (CTL, Tc): recognise antigenic peptides presented on MHC I molecules (on all nucleated cells). They kill virus‑infected cells and tumour cells using perforin/granzymes and Fas–FasL pathways.
• CD4+ Helper T cells (Th): recognise peptides on MHC II (on antigen‑presenting cells). They secrete cytokines and differentiate into subsets: Th1 (cellular immunity, activates macrophages and CTLs), Th2 (humoral immunity, helps B cells), Th17 (inflammation), Tfh (help B cells in germinal centres).
• Regulatory T cells (Treg): maintain self‑tolerance and suppress excessive immune responses.
• Memory T cells: long-lived cells that provide rapid, amplified responses on re‑exposure to antigen.

Antigen processing & presentation — two main pathways

• MHC I pathway: Endogenous antigens (viral or abnormal intracellular proteins) are degraded by proteasomes, peptides transported into ER by TAP, loaded onto MHC I, and presented to CD8+ T cells.
• MHC II pathway: Exogenous antigens taken up by endocytosis are processed in endosomes/lysosomes, loaded onto MHC II in antigen presenting cells (dendritic cells, macrophages, B cells), and presented to CD4+ T cells.

Activation of naive T cells — key steps

1. Antigen recognition: T cell receptor (TCR) binds specific peptide–MHC complex.
2. Co-stimulation: Second signals (e.g., CD28 on T cell binding B7/CD80–CD86 on APC) are required to avoid anergy.
3. Cytokine signals: Cytokines from APCs and local environment direct differentiation (IL-12 → Th1, IL-4 → Th2, etc.).
4. Clonal expansion and differentiation: Activated T cells proliferate and become effector and memory cells.
5. Effector functions: CTLs kill target cells; Th cells activate macrophages, help B cells and orchestrate the immune response.

Mechanisms of target-cell killing by CD8+ T cells

• Perforin‑granzyme pathway: Perforin forms pores in the target cell membrane; granzymes enter and induce apoptosis.
• Fas–FasL interaction: Binding of FasL on T cell to Fas on target triggers apoptotic signalling.

Biological outcomes and importance

• Elimination of intracellular pathogens (viruses, some bacteria, protozoa).
• Anti-tumour immunity by recognising tumour‑specific or tumour‑associated antigens.
• Role in transplant rejection (host T cells recognise donor MHC/peptides).
• Contribution to delayed-type hypersensitivity (Type IV hypersensitivity) — e.g., tuberculin reaction.
• Memory T cells provide faster and stronger secondary responses — principle behind many vaccines.

Regulation and clinical relevance

• Autoimmunity: Faulty regulation of T cells can cause diseases like type 1 diabetes, rheumatoid arthritis.
• Immunodeficiency: HIV infects CD4+ T cells causing loss of helper function and opportunistic infections.
• Immunotherapy: Cancer therapies (e.g., checkpoint inhibitors, CAR‑T cells) harness or modify T cell responses.

Summary (concise)

T-cell mediated immunity is essential for defence against intracellular pathogens and abnormal cells, relies on antigen presentation via MHC molecules, requires antigen recognition plus co-stimulation for activation, and produces effector and memory T cells that kill targets directly or regulate other immune cells.

Fig 17 — Educational Diagram: Antigen Processing and Presentation

Definition & significance: Antigen processing and presentation is the cellular mechanism by which protein antigens are degraded into short peptide fragments and displayed on the cell surface bound to Major Histocompatibility Complex (MHC) molecules so that T lymphocytes can recognize them. This process links innate detection of foreign material to activation of adaptive immunity (T cells), and is essential for fighting infections, forming immunological memory, and for vaccine responses.

Main components:

• Antigen-presenting cells (APCs): Dendritic cells, macrophages, B cells (professional APCs). Nearly all nucleated cells can present via MHC I.
• MHC molecules: MHC class I (expressed on nearly all nucleated cells) and MHC class II (expressed mainly on professional APCs).
• T cells: CD8+ T cells recognize peptides on MHC I; CD4+ T helper cells recognize peptides on MHC II.

Two classical pathways:

1. Endogenous (MHC I) pathway — presents intracellular antigens (e.g., viral proteins, mutated proteins):

• Cytosolic proteins (normal or viral) are ubiquitinated and degraded by the proteasome into peptides.
• Peptides are transported into the endoplasmic reticulum (ER) by TAP (Transporter associated with Antigen Processing).
• In the ER, peptides are loaded onto newly synthesized MHC class I molecules; peptide–MHC I complexes are transported to the cell surface in vesicles.
• Displayed peptide–MHC I is scanned by CD8+ (cytotoxic) T cells; recognition can trigger killing of the infected cell.

2. Exogenous (MHC II) pathway — presents extracellular antigens (e.g., bacteria, soluble proteins):

• APCs take up extracellular antigen by phagocytosis, endocytosis or receptor-mediated uptake into endosomes/lysosomes.
• Proteases in the endosome/lysosome degrade antigen into peptides.
• MHC class II α and β chains are synthesized in the ER with an invariant chain (Ii) blocking the peptide-binding groove to prevent premature loading.
• MHC II–Ii complexes traffic to endosomal compartments where Ii is degraded, leaving CLIP, and HLA-DM (in humans) facilitates exchange of CLIP for antigenic peptides.
• Peptide–MHC II complexes are transported to the cell surface for recognition by CD4+ helper T cells.

Other important concepts:

• Cross-presentation: Some dendritic cells can present extracellular antigens on MHC I (useful for initiating CD8+ responses to viruses that do not infect DCs).
• Co-stimulation and cytokines: For full T cell activation, peptide–MHC recognition must be accompanied by co-stimulatory signals (e.g., B7 on APC binding CD28 on T cell) and cytokines; without co-stimulation, T cells may become anergic.
• Superantigens: Certain bacterial toxins (e.g., Staphylococcal enterotoxins) bind outside the peptide groove and link MHC II to TCRs nonspecifically, causing massive T cell activation and cytokine storm.
• Clinical relevance: Vaccines depend on APC uptake and presentation to generate helper and cytotoxic T cell responses; transplant rejection is driven by recognition of foreign MHC; defects in processing (e.g., TAP deficiency, Bare Lymphocyte Syndrome) cause immune deficiency.

Step-by-step simplified flow (summary):

• Antigen uptake → Processing into peptides → Loading on MHC (I or II) → Transport to cell surface → Recognition by appropriate T cell → T cell activation → Effector response.

Tips to remember: MHC I = Intracellular (endogenous), presents to CD8+; MHC II = Extracellular (exogenous), presents to CD4+. Proteasome & TAP are key for MHC I; endosomal proteases, invariant chain and HLA-DM are key for MHC II.

Illustrative diagram ideas (see graphs section): Show proteasome/TAP/ER route on one side and phagolysosome/MHC II route on the other; depict T cell receptor contact with peptide–MHC complex and co-stimulatory molecules between APC and T cell.

Fig 18 — Educational Diagram: Complement System

What is the complement system?

The complement system is a set of >30 plasma and membrane-associated proteins that form an enzymatic cascade and bridge innate and adaptive immunity. When activated, complements tag pathogens, recruit inflammatory cells, and directly lyse target cell membranes.

Major functions

• Opsonization: C3b coats microbes to enhance phagocytosis.
• Inflammation and chemotaxis: small fragments (C3a, C5a) act as anaphylatoxins and chemoattractants.
• Direct lysis: formation of the membrane attack complex (MAC, C5b–C9) creates pores in microbial membranes.
• Immune complex clearance: complement helps remove antigen–antibody complexes and apoptotic cells.

Activation pathways (overview)

• Classical pathway — initiated by C1 binding to antigen–antibody complexes (IgM or IgG). Produces C3 convertase C4b2a.
• Lectin pathway — initiated by mannose-binding lectin (MBL) binding to microbial carbohydrates; similar downstream events to classical, producing C4b2a.
• Alternative pathway — initiated directly on pathogen surfaces by spontaneous hydrolysis of C3 (tickover) and stabilized by properdin; produces C3 convertase C3bBb.

Core cascade (simplified)

All pathways converge at C3 cleavage: C3 → C3a (inflammatory mediator) + C3b (opsonin). C3b participates in forming C5 convertase, which cleaves C5 → C5a (potent chemoattractant) + C5b (initiates MAC assembly). C5b recruits C6, C7, C8 and multiple C9 molecules to form the pore-forming MAC (C5b-9).

Regulation

• Plasma and membrane regulators prevent host damage: C1 inhibitor (C1INH) blocks C1 activation; Factor H and Factor I inactivate C3b; CD55 (DAF) disrupts convertases; CD59 prevents MAC formation on host cells.

Clinical relevance

• Deficiencies: MAC component deficiencies (C5–C9) increase susceptibility to Neisseria infections. C1 inhibitor deficiency causes hereditary angioedema (excess bradykinin-mediated edema).
• Autoimmunity: defective complement-mediated clearance of immune complexes can contribute to SLE.
• Pathogen evasion: encapsulated bacteria (e.g., Streptococcus pneumoniae) resist complement; some microbes express proteins that bind Factor H to evade opsonization.

Summary

The complement system is a rapid, amplifying cascade that helps recognize and eliminate microbes, enhances inflammation and phagocytosis, and must be tightly regulated to avoid host tissue damage.

Fig 19 — Educational Diagram: Hypersensitivity and Allergy

Overview
Hypersensitivity is an exaggerated or inappropriate immune response that causes host tissue damage. "Allergy" is commonly used for IgE‑mediated (Type I) hypersensitivity but in medicine hypersensitivity includes four types (I–IV) based on mechanism, time course and mediators.

Classification and mechanisms

• Type I — Immediate (IgE mediated)
  Mechanism: First exposure to an allergen leads to Th2 activation, IL‑4/IL‑13 driven class switching of B cells to produce IgE. IgE binds FcεRI receptors on mast cells and basophils (sensitisation). On re‑exposure the allergen cross‑links IgE on these cells causing degranulation and release of histamine, tryptase, heparin, leukotrienes and prostaglandins. Effects: vasodilation, increased vascular permeability, bronchoconstriction, mucus secretion, itch.
• Type II — Antibody mediated (cytotoxic)
  Mechanism: IgG or IgM directed against antigens on cell surfaces or extracellular matrix. Binding leads to complement activation, opsonisation and phagocytosis or antibody dependent cellular cytotoxicity (ADCC). Examples: transfusion reactions (ABO incompatibility), autoimmune hemolytic anemia, some forms of pemphigus.
• Type III — Immune complex mediated
  Mechanism: Soluble antigen binds antibody forming immune complexes that deposit in vessel walls or tissues. Complexes activate complement, attract neutrophils and cause enzyme‑mediated tissue injury. Time course: hours to days. Examples: serum sickness, post‑streptococcal glomerulonephritis, some manifestations of SLE.
• Type IV — Delayed (cell mediated)
  Mechanism: T lymphocytes (Th1, CD8+ Tc cells) recognize antigen and release cytokines (eg, IFN‑γ, TNF) that activate macrophages or effect direct cytotoxicity. Reaction occurs 48–72 hours after exposure. Examples: tuberculin (Mantoux) test, contact dermatitis (poison ivy, nickel), graft rejection.

Clinical features and diagnosis

• Type I: rhinitis, conjunctivitis, urticaria (hives), bronchial asthma, anaphylaxis. Tests: skin prick test, specific serum IgE (RAST/ImmunoCAP).
• Type II: hemolysis, thrombocytopenia, tissue‑specific autoimmune disease. Tests: direct/indirect Coombs test, antigen/antibody detection.
• Type III: fever, rash, arthritis, nephritis. Tests: complement levels (often low), immune complex assays.
• Type IV: localized redness, induration. Tests: patch test (contact dermatitis), tuberculin skin test.

Treatment and prevention

• Type I: avoid allergen, antihistamines, inhaled/oral corticosteroids, bronchodilators for asthma, epinephrine for anaphylaxis, allergen immunotherapy (desensitisation).
• Type II/III/IV: remove offending antigen/drug, immunosuppressive therapy (steroids, disease‑modifying drugs), plasmapheresis in severe antibody/complex mediated disease.

Key points

• Allergy usually means Type I hypersensitivity (IgE). Hypersensitivity is a broader term including Types I–IV.
• Time course differs: immediate (minutes) for Type I, immune complex reactions within hours–days, delayed cell mediated in 48–72 hours.
• Different diagnostic tests and treatments are used for each type; correct classification guides management.

Fig 20 — Educational Diagram: Autoimmune Diseases

Definition: Autoimmune diseases are conditions in which the immune system mistakenly recognises the body's own cells, tissues or organs as foreign and mounts an immune response against them, causing chronic damage and dysfunction.

Basic mechanism: The immune system normally distinguishes self from non-self by central and peripheral tolerance mechanisms. Autoimmunity occurs when tolerance fails, producing autoreactive T cells and/or autoantibodies. Key processes include:

• Loss of self-tolerance — defects in thymic selection (central tolerance) or peripheral regulatory mechanisms (e.g., Treg cells).
• Molecular mimicry — foreign antigens (often microbial) resemble self-antigens, triggering cross-reactive immune responses.
• Epitope spreading — initial immune response expands to target additional self-epitopes.
• Immune complex deposition — antigen–antibody complexes deposit in tissues activating complement and inflammation (typical of systemic autoimmunity).
• Cell-mediated cytotoxicity — autoreactive CD8+ T cells directly kill target cells (common in organ-specific autoimmunity).

Classification:

• Organ-specific autoimmune diseases — immune attack is directed at a single organ or cell type (examples: Type 1 diabetes pancreas β-cells, Hashimoto's thyroiditis).
• Systemic autoimmune diseases — multiple organs and systems are involved (examples: Systemic lupus erythematosus, rheumatoid arthritis).

Pathogenesis (summary): Genetic predisposition (HLA alleles), environmental triggers (infections, drugs, toxins), hormonal factors (higher prevalence in females), and immune dysregulation combine to break tolerance. Autoantibodies and autoreactive T cells cause inflammation through complement activation, Fc receptor–mediated phagocytosis, cytokine release and direct cytotoxicity, leading to tissue injury and clinical disease.

Clinical features & diagnosis: Symptoms vary by disease but commonly include chronic inflammation, fatigue, organ-specific dysfunction (e.g., hypothyroidism, hyperglycaemia, joint pain). Diagnosis uses serology (autoantibodies such as ANA, anti-dsDNA, anti-TPO, anti-GAD, RF, anti-CCP), functional tests (thyroid function tests, blood glucose), imaging and sometimes biopsy. Important diagnostic concepts include test sensitivity, specificity and antibody titre interpretation.

Treatment principles: There is no universal cure. Treatments aim to reduce immune-mediated damage and manage symptoms:

• Immunosuppressive drugs (corticosteroids, methotrexate, azathioprine).
• Targeted biologicals (TNF inhibitors, anti-CD20 — rituximab) for some conditions.
• Plasmapheresis to remove pathogenic autoantibodies in selected acute cases.
• Replacement therapy when organ function is lost (insulin for type 1 diabetes, thyroid hormone for hypothyroidism).
• Supportive care: physiotherapy, pain control, infection prevention.

Prevention & prognosis: True prevention is difficult. Early diagnosis and therapy reduce irreversible damage. Prognosis varies: some diseases can be controlled long-term; others cause progressive disability or life-threatening complications if untreated.

Summary (Class 12 focus): Autoimmune diseases arise from a breakdown of immune tolerance leading to autoantibodies and autoreactive T cells. They are classified as organ-specific or systemic and are diagnosed by clinical features and specific laboratory tests. Management uses immunosuppression, biologic agents and organ-specific replacement therapies.

Fig 21 — Educational Diagram: Immunodeficiency Disorders

Definition: Immunodeficiency disorders are conditions in which one or more components of the immune system are absent or dysfunctional, leading to increased susceptibility to infections, poor response to vaccines and, in some cases, autoimmunity or malignancy.

Classification

• Primary (congenital) immunodeficiencies: Caused by inherited genetic defects that directly affect immune cells or molecules. Usually present in infancy or childhood. Examples: Severe Combined Immunodeficiency (SCID), X‑linked agammaglobulinemia, DiGeorge syndrome, Chronic Granulomatous Disease (CGD).
• Secondary (acquired) immunodeficiencies: Caused by external factors that impair immune function. Can occur at any age. Examples: HIV/AIDS, malnutrition, chemotherapy, long‑term corticosteroid use, diabetes mellitus.

Basic Pathophysiology

• Defects in B cells cause impaired antibody production → recurrent bacterial infections, especially of the respiratory tract.
• Defects in T cells affect cell‑mediated immunity → severe viral, fungal, and opportunistic infections.
• Combined B‑ and T‑cell defects (as in SCID) result in severe, life‑threatening infections early in life.
• Defects in phagocytes (neutrophils, macrophages) lead to poor killing of ingested microbes → formation of granulomas, recurrent abscesses (e.g., CGD).
• Complement deficiencies predispose to specific bacterial infections and impaired immune complex clearance.

Clinical Features

• Recurrent, severe or unusual infections (opportunistic organisms).
• Poor wound healing, chronic diarrhea, failure to thrive (in children).
• Persistent thrush, pneumonias, meningitis, skin abscesses.
• Family history of early deaths from infection suggests inherited immunodeficiency.

Diagnosis (Common Tests)

• Complete blood count with differential (look for lymphopenia, neutropenia).
• Absolute lymphocyte and neutrophil counts (see formulas provided).
• Serum immunoglobulin levels (IgG, IgM, IgA, IgE).
• Flow cytometry to quantify T, B, and NK cells (CD4+, CD8+, CD19+, CD56+).
• Functional assays: nitroblue tetrazolium (NBT) or dihydrorhodamine (DHR) for neutrophil oxidative burst (CGD); vaccine response assessment for humoral function.
• Specific tests for HIV (ELISA, rapid tests, PCR for viral RNA) in suspected secondary immunodeficiency.

Treatment and Management

• Treat infections promptly with appropriate antimicrobials.
• Replacement therapy: intravenous or subcutaneous immunoglobulin (IVIG/SCIG) for antibody deficiencies.
• Hematopoietic stem cell (bone marrow) transplantation for severe congenital disorders (e.g., SCID).
• Antiviral therapy (antiretroviral therapy, ART) for HIV/AIDS to restore immune function.
• Gene therapy is emerging for some genetic immunodeficiencies (e.g., ADA‑SCID).
• Avoid live attenuated vaccines in severe immunodeficiency; ensure household contacts are immunized.

Prevention & Prognosis

• Early diagnosis improves outcomes — screening (newborn) and family genetic counseling for inherited disorders.
• Good nutrition, infection control, prophylactic antimicrobials in select cases.
• Prognosis varies: from manageable chronic disease (with IVIG or ART) to life‑threatening (untreated SCID).

Key Points for Class 12 (CBSE)

• Know the difference between primary and secondary immunodeficiency with examples.
• Understand the impact of T‑cell loss (e.g., HIV depleting CD4+ cells) and B‑cell/antibody deficiencies.
• Recognize clinical clues: recurrent/opportunistic infections, family history, poor vaccine response.

Fig 22 — Educational Diagram: HIV and AIDS

Definition: Human Immunodeficiency Virus (HIV) is a retrovirus that infects cells of the immune system, primarily CD4+ T lymphocytes. Acquired Immunodeficiency Syndrome (AIDS) is the advanced clinical stage of HIV infection marked by severe immune deficiency and opportunistic infections.

Causative agent and types: HIV is an enveloped RNA retrovirus (family Retroviridae). Two main types: HIV‑1 (globally common, more virulent) and HIV‑2 (mainly West Africa, slower progression).

Structure (brief): spherical, envelope with glycoproteins gp120 and gp41, capsid containing two copies of +ssRNA, and key enzymes: reverse transcriptase (RT), integrase, and protease.

Replication cycle (key steps):

• Attachment: gp120 binds CD4 receptor and a co‑receptor (CCR5 or CXCR4) on host cells.
• Fusion and entry: viral envelope fuses with host membrane; core enters cytoplasm.
• Reverse transcription: viral RNA → DNA by RT (error‑prone).
• Integration: viral DNA (provirus) integrates into host genome via integrase.
• Transcription/translation: host machinery produces viral RNA and proteins.
• Assembly and budding: immature virions bud from membrane; protease cleaves Gag/Pol to mature infectious virions.

Pathogenesis: HIV infects and destroys CD4+ T cells and impairs immune function. Early infection shows high viremia and acute symptoms. A clinically latent phase follows with progressive CD4 decline. When CD4 count falls below critical levels (e.g., <200 cells/µL) or opportunistic infections/cancers appear, AIDS is diagnosed.

Clinical stages: acute/primary infection (flu‑like illness), clinical latency (months–years, often asymptomatic), symptomatic HIV infection (persistent generalized lymphadenopathy, weight loss), and AIDS (opportunistic infections like Pneumocystis pneumonia, TB, candidiasis; malignancies such as Kaposi's sarcoma).

Diagnosis: screening by antibody/antigen tests (rapid tests, ELISA; 4th generation tests detect p24 antigen + antibodies). Confirmatory testing (Western blot historically; now algorithmic confirmatory assays). Nucleic acid tests (PCR) detect viral RNA—used for early detection (window period) and viral load measurement.

Treatment (principles): Antiretroviral therapy (ART) — combination therapy using drugs from different classes to suppress viral replication, restore/maintain immune function, and prevent resistance. Major drug classes: NRTIs, NNRTIs, protease inhibitors, integrase strand transfer inhibitors (INSTIs), fusion/entry inhibitors. Early and lifelong ART is standard of care; treatment reduces viral load to undetectable levels and greatly lowers transmission risk ("U=U": undetectable = untransmittable).

Prevention: safe sex (condoms), harm reduction for injecting drug users (needle exchange), screening of blood products, prevention of mother‑to‑child transmission (PMTCT: maternal ART, infant prophylaxis, safer delivery and feeding practices), pre‑exposure prophylaxis (PrEP), post‑exposure prophylaxis (PEP), education and stigma reduction.

Public health and social aspects: HIV carries significant stigma; counseling, confidentiality, and community support are essential. Regular testing, contact tracing in public‑health contexts, and equitable access to ART are critical to control the epidemic.

Key points for students:

• Understand viral structure and the reason for high mutation rate (error‑prone reverse transcriptase) leading to drug resistance and immune escape.
• Know modes of transmission: unprotected sexual contact, contaminated blood products/needles, mother‑to‑child (in utero, intrapartum, breast‑feeding).
• Recognize diagnostic tests and the concept of window period and viral load/CD4 monitoring.

Fig 23 — Educational Diagram: Vaccination and Immunization

Definition

Vaccination is the administration of a vaccine (antigenic material) to stimulate an individual's immune system to develop adaptive immunity to a pathogen. Immunization is the process by which a person becomes protected against a disease through vaccination or through recovery from the disease.

Basic principles

• Vaccines present a safe form of antigen so the immune system can form memory cells without causing the disease.
• On first exposure (primary response) B cells produce mainly IgM, later IgG; memory B and T cells form. On re-exposure (secondary/booster) response is faster, stronger and dominated by IgG.
• Active immunity: host produces own antibodies and memory (long-term). Passive immunity: preformed antibodies given (short-term).

Types of vaccines

• Live attenuated: weakened pathogen (e.g., measles, mumps, rubella). Strong, long-lasting immunity but not for immunocompromised.
• Inactivated (killed): whole killed organism (e.g., inactivated polio vaccine). Safer but may need boosters.
• Subunit/conjugate: purified antigens or polysaccharides linked to a carrier (e.g., HepB, Hib).
• Toxoid: inactivated toxins (e.g., tetanus, diphtheria).
• Recombinant, DNA, mRNA and viral vector: use genetic technology to express antigen (e.g., HepB recombinant; COVID-19 mRNA and viral vector vaccines).

Mechanism (overview)

1. Antigen uptake by antigen-presenting cells (APCs) → processing and presentation on MHC molecules.
2. Activation of helper T cells (CD4+) → cytokine signals to B cells and cytotoxic T cells.
3. B cell activation, proliferation, class switching (IgM → IgG/IgA), affinity maturation and formation of memory B cells and plasma cells.
4. On re-exposure, memory cells mount a rapid secondary response with higher-affinity antibodies.

Key public-health concepts

• Herd immunity: when a large fraction of a population is immune, transmission chains are interrupted and unvaccinated individuals are protected indirectly.
• Cold chain: many vaccines require controlled temperature storage from manufacture to administration to retain potency.
• Booster doses restore waning immunity by eliciting a secondary response.

Safety, contraindications and side effects

• Most vaccines cause mild local or systemic side effects (fever, soreness). Serious reactions are rare.
• Live attenuated vaccines are usually contraindicated in severely immunocompromised persons and during pregnancy.
• Vaccine safety is monitored by post-marketing surveillance to detect adverse events.

Class 12 level emphasis

Understand the difference between vaccination and immunization, types of vaccines, the immune mechanisms (primary vs secondary response, role of memory cells), herd immunity concept and simple formulas for herd threshold and vaccine efficacy.

Fig 24 — Educational Diagram: Diagnosis of Infectious Diseases

Diagnosis of infectious diseases means identifying the causative agent and the state of infection in a patient so appropriate treatment and public‑health action can be taken. Diagnosis combines clinical assessment (history, symptoms, signs) with laboratory methods that detect the pathogen itself, its components (antigen, nucleic acid), or the host response (antibodies).

Major steps in laboratory diagnosis:

• Specimen collection and transport: choose correct specimen (blood, urine, sputum, CSF, swabs), collect aseptically, and transport under recommended conditions to preserve viability/antigens/RNA.
• Direct detection: microscopic examination and staining (e.g., Gram stain, Ziehl–Neelsen for Mycobacterium tuberculosis, Giemsa for malaria parasites) to see organisms directly.
• Culture and isolation: grow bacteria/fungi on selective media for identification and antibiotic susceptibility. Culture is gold standard for many bacterial infections but may take time.
• Antigen detection and rapid tests: lateral flow assays and ELISA detect pathogen proteins (e.g., dengue NS1, malaria RDTs, rapid antigen tests for SARS‑CoV‑2). They are fast but vary in sensitivity.
• Nucleic acid based tests (NAATs): PCR, RT‑PCR and real‑time PCR detect pathogen DNA/RNA with high sensitivity and specificity. Useful for early detection and quantitation (viral load). Quantitative PCR uses Ct (cycle threshold) values to infer starting amount.
• Serology (antibody tests): detect host antibodies (IgM, IgG) against the pathogen (ELISA, agglutination). Useful for retrospective diagnosis or when pathogen is hard to isolate. Note: antibodies appear after a window period.
• Imaging and ancillary tests: chest X‑ray, CT, and other tests can support diagnosis (e.g., TB, pneumonia) but do not identify the microbe.

Interpretation and confirmation:

• Screening tests (fast, high sensitivity) are followed by confirmatory tests (high specificity) to avoid false positives.
• Consider false negatives (due to low pathogen load or early infection) and false positives (cross‑reactivity, contamination).
• Combine laboratory results with clinical context, epidemiology and exposure history for accurate diagnosis.

Advantages and limitations (summary):

• Microscopy: rapid, cheap but requires skilled personnel and may lack sensitivity.
• Culture: definitive and allows susceptibility testing but time‑consuming.
• Antigen tests & rapid tests: quick and field‑usable but sensitivity varies.
• PCR/NAAT: very sensitive and specific, detects early infection, but needs lab infrastructure and has risk of contamination.
• Serology: good for past exposure and immune status but limited in early infection due to window period.

Quality indicators and public health use: accurate diagnosis guides therapy, infection control and epidemiological surveillance (case confirmation, outbreak investigation, monitoring treatment response).

Fig 25 — Educational Diagram: Chemotherapy and Antimicrobial Agents

Overview
Chemotherapy in the context of infectious disease means using chemical agents to kill or inhibit pathogenic microorganisms. Antimicrobial agents include antibiotics (for bacteria), antivirals, antifungals, antiprotozoals and antihelminthics. The key principle is selective toxicity: harm the pathogen without injuring the host.

Main classes and targets

• Cell wall synthesis inhibitors: β-lactams (penicillins, cephalosporins), glycopeptides (vancomycin) — act on peptidoglycan synthesis.
• Protein synthesis inhibitors: act on bacterial ribosomes (30S or 50S) — aminoglycosides, tetracyclines (30S); macrolides, chloramphenicol (50S).
• Metabolic pathway inhibitors: sulfonamides and trimethoprim inhibit folic acid synthesis required for nucleotides.
• Nucleic acid synthesis inhibitors: quinolones inhibit DNA gyrase; some agents block RNA polymerase.
• Membrane disruptors: polymyxins (alter membrane permeability).
• Antivirals, antifungals, antiprotozoals: target virus-specific enzymes (e.g., reverse transcriptase), fungal ergosterol, protozoan metabolic pathways.

Pharmacological concepts

• Therapeutic index (TI): measure of drug safety (higher is safer).
• Minimum Inhibitory Concentration (MIC): lowest concentration that prevents visible growth. MIC guides dosing.
• Time-dependent vs concentration-dependent killing: some drugs work best if serum levels remain above MIC (time-dependent), others if peak concentrations are high (concentration-dependent).

Resistance mechanisms

• Enzymatic drug inactivation (e.g., β-lactamases).
• Modification of drug target (altered ribosomal binding sites, modified PBPs).
• Reduced permeability or increased efflux pumps.
• Acquisition of resistance genes by horizontal gene transfer.

Clinical considerations and stewardship
Rational use of antimicrobials (right drug, dose, duration) prevents resistance and adverse effects. Combination therapy is used to broaden spectrum, prevent resistance, or obtain synergistic effects (but may cause antagonism). Side effects range from allergic reactions to organ toxicity and disturbance of normal flora (superinfections).

Distinguishing chemotherapy for cancer vs antimicrobials
Both are chemical therapies. Antimicrobials target microorganisms; anticancer chemotherapy targets rapidly dividing host cells and has different toxicity and monitoring requirements.

Fig 26 — Educational Diagram: Antimicrobial Resistance

Definition: Antimicrobial resistance (AMR) is the ability of microorganisms (bacteria, viruses, fungi, parasites) to survive exposure to an antimicrobial drug that would normally kill them or stop their growth. In bacteria this is commonly called antibiotic resistance.

Why it matters: AMR makes standard treatments ineffective, leads to persistent infections, increases risk of spread, raises healthcare costs, and causes higher morbidity and mortality.

How resistance arises (conceptual overview):strong